• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $CADL

    Candel Therapeutics Inc.

    Subscribe to $CADL
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of cancer immunotherapy drugs. The company offers Gene Mediated Cytotoxic Immunotherapy technology-based drugs that are designed to work with radiation, chemotherapy, and surgery to eradicate residual tumor cells that could lead to recurrence or metastases. Its product candidates include CAN-2409, an off-the-shelf adenovirus product candidate, for the treatment of localized, primary prostate cancer and therapy for pancreatic cancer; and CAN-3110, its HSV product candidate, has been engineered for enhanced specificity and tumor cell killing, while minimizing toxicity on healthy tissue and indicated for the treatment of recurrent high-grade glioma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was founded in 1999 and is based in Needham, Massachusetts.

    IPO Year: 2021

    Exchange: NASDAQ

    Website: candeltx.com

    Recent Analyst Ratings for Candel Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    2/20/2025$25.00Buy
    Citigroup
    2/19/2025$20.00Buy
    Canaccord Genuity
    2/7/2025$15.00Buy
    BofA Securities
    12/2/2022$11.00Buy
    H.C. Wainwright
    11/19/2021$18.00Outperform
    BMO Capital
    8/23/2021$9.00Buy
    UBS
    8/23/2021$22.00Buy
    Jefferies
    8/23/2021$15.00Outperform
    Credit Suisse
    See more ratings

    Candel Therapeutics Inc. SEC Filings

    See more
    • Candel Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Candel Therapeutics, Inc. (0001841387) (Filer)

      6/18/25 8:30:50 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Candel Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Candel Therapeutics, Inc. (0001841387) (Filer)

      6/6/25 8:11:04 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Candel Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Candel Therapeutics, Inc. (0001841387) (Filer)

      5/28/25 8:10:40 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Candel Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Candel Therapeutics, Inc. (0001841387) (Filer)

      5/22/25 5:12:48 PM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Candel Therapeutics Inc.

      SCHEDULE 13G/A - Candel Therapeutics, Inc. (0001841387) (Subject)

      5/15/25 4:33:28 PM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Candel Therapeutics Inc.

      10-Q - Candel Therapeutics, Inc. (0001841387) (Filer)

      5/13/25 8:30:40 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Candel Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Candel Therapeutics, Inc. (0001841387) (Filer)

      5/13/25 8:15:10 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Candel Therapeutics Inc.

      DEFA14A - Candel Therapeutics, Inc. (0001841387) (Filer)

      4/29/25 4:08:48 PM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Candel Therapeutics Inc.

      DEF 14A - Candel Therapeutics, Inc. (0001841387) (Filer)

      4/29/25 4:05:15 PM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Candel Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Candel Therapeutics, Inc. (0001841387) (Filer)

      4/23/25 4:15:31 PM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Candel Therapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Benz Edward J. Jr

      4 - Candel Therapeutics, Inc. (0001841387) (Issuer)

      6/18/25 8:38:15 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Gaeta Renee

      4 - Candel Therapeutics, Inc. (0001841387) (Issuer)

      6/18/25 8:37:10 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Loggia Nicoletta

      4 - Candel Therapeutics, Inc. (0001841387) (Issuer)

      6/18/25 8:36:23 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Manning Paul B

      4 - Candel Therapeutics, Inc. (0001841387) (Issuer)

      6/18/25 8:35:33 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Martell Christopher

      4 - Candel Therapeutics, Inc. (0001841387) (Issuer)

      6/18/25 8:34:55 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Nabel Gary J.

      4 - Candel Therapeutics, Inc. (0001841387) (Issuer)

      6/18/25 8:33:55 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Nguyen Diem

      4 - Candel Therapeutics, Inc. (0001841387) (Issuer)

      6/18/25 8:33:20 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Papa Joseph C

      4 - Candel Therapeutics, Inc. (0001841387) (Issuer)

      6/18/25 8:32:30 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Radhakrishnan Maha

      4 - Candel Therapeutics, Inc. (0001841387) (Issuer)

      6/6/25 4:36:10 PM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Radhakrishnan Maha

      3 - Candel Therapeutics, Inc. (0001841387) (Issuer)

      6/6/25 4:31:09 PM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care